Business
GSK Nuvalent acquisition talks: FT reports talks to buy
GSK is reportedly in talks to acquire Nuvalent, a cancer treatment company, with a price range cited between $9 billion and $10 billion, according…
GSK is reportedly in talks to acquire Nuvalent, a cancer treatment company, with a price range cited between $9 billion and $10 billion, according…